Logo
x

Search

Subscribe Now

Takeda

Takeda Receives Health Canada’s Approval for Fruzaqla (fruquintinib) to Treat Metastatic Colorectal Cancer (mCRC)

Takeda Receives Health Canada’s Approval for Fruzaqla (fruquintinib) to Treat Metastatic Colorectal Cancer (mCRC)

  • January 21, 2025
Takeda’s Hyqvia 10% SC Injection Receives the Japanese Approval to Treat Agammaglobulinemia or Hypogammaglobulinemia

Takeda’s Hyqvia 10% SC Injection Receives the Japanese Approval to Treat Agammaglobulinemia or Hypogammaglobulinemia

  • December 27, 2024
Takeda at UEG Week 2024: Marcelo Freire from Takeda in an Enlightening Conversation with PharmaShots

Takeda at UEG Week 2024: Marcelo Freire from Takeda in an Enlightening Conversation with PharmaShots

  • December 2, 2024
Takeda Reports the MHLW’s Approval of Fruzaqla (Fruquintinib) to Treat Unresectable Advanced or Recurrent Colorectal Cancer (CRC)

Takeda Reports the MHLW’s Approval of Fruzaqla (Fruquintinib) to Treat Unresectable Advanced or Recurrent Colorectal Cancer (CRC)

  • September 25, 2024
Takeda Reports the EC’s Approval of Adzynma to Treat Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Reports the EC’s Approval of Adzynma to Treat Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

  • August 7, 2024
Takeda’s Fruzaqla Gains the EC’s Approval for the treatment of Metastatic Colorectal Cancer

Takeda’s Fruzaqla Gains the EC’s Approval for the treatment of Metastatic Colorectal Cancer

  • June 25, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.